NASDAQ:LABP
Landos Biopharma, Inc. Stock News
$22.30
+0.0900 (+0.405%)
At Close: May 21, 2024
Landos Biopharma to Participate in Upcoming Investor Events
07:00am, Thursday, 05'th Aug 2021
BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel
Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference
05:08pm, Monday, 14'th Jun 2021
BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and dev
The FDA clears the path to initiate the PACIFY I and II global registration studies in Mild-to-Moderate Active UC patients representing the potential for a broad product label for Omilancor The FDA cl
Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference
07:00am, Tuesday, 25'th May 2021
BLACKSBURG, Va., May 25, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop novel
Week In Review: LianBio Acquires 2 IBD Candidates In $218 Million Deal
11:15pm, Sunday, 23'rd May 2021
LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. Ji Xing Pharma of Shanghai acquired Greater China rights to
Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors
07:00am, Wednesday, 19'th May 2021
BLACKSBURG, Va., May 19, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients
Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China
09:29am, Monday, 17'th May 2021
Landos Biopharma Inc (NASDAQ: LABP) and LianBio have announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China
Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates
07:15am, Monday, 17'th May 2021
Completed initial public offering of common stock, raising approximately $100 million in gross proceeds
BLACKSBURG, Va., April 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients wi
Landos Biopharma Stock Is Trading Higher On Initiating Early-Stage Study With Omilancor For Esophagus Inflammation
09:53am, Tuesday, 06'th Apr 2021
The FDA has signed off Landos Biopharma's (NASDAQ: LABP) Investigational New Drug application for omilancor (BT-11) for the treatment of Eosinophilic Esophagitis (EoE). Landos expects to initiate
Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis
07:00am, Tuesday, 06'th Apr 2021
Third potential indication for omilancor (BT-11), a first-in-class candidate for the treatment of autoimmune diseases Third potential indication for omilancor (BT-11), a first-in-class candidate for t
U.S. IPO Weekly Recap: Biotechs Flood The IPO Market In A 14 IPO Week
02:14am, Monday, 08'th Feb 2021
The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. German chemicals group Atotech downsized and priced below the range to raise $498
A Busy Day for Biotech IPOs
02:35pm, Thursday, 04'th Feb 2021
Three biotechs—Sana Biotechnology, Landos Biopharma, Sensei Biotherapeutics—and chemicals specialist Atotech made their public-market debut Thursday. Here's how they fared.
Landos Biopharma Announces Pricing of Initial Public Offering
08:13pm, Wednesday, 03'rd Feb 2021
BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune di